| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8272045 | Journal of Geriatric Oncology | 2018 | 7 Pages |
Abstract
Despite treatment with novel agents for RRMM in 86% of patients, an outcome gap persists for older patients and those with RI and/or CVD. Personalized treatment approaches that account for age and comorbidities, and further evaluation of innovative regimens and dosing schedules, are needed to improve outcomes for these patients.
Keywords
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Ageing
Authors
Parameswaran Hari, Dorothy Romanus, Katarina Luptakova, Marlo Blazer, Candice Yong, Aditya Raju, Eileen Farrelly, Richard Labotka, Vicki A. Morrison,